Use of rituximab in histologically confirmed idiopathic inflammatory myositis: a case series

Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks

Stanley Cohen, Paul Emery, Maria Greenwald et al. · Arthritis & Rheumatism · 2006 · 1.6K citations

Medicine, Pharmacology, Pharmacotherapy +16

Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo‐phase trial

Chester V. Oddis, Ann M. Reed, Rohit Aggarwal et al. · Arthritis & Rheumatism · 2012 · 691 citations

Medicine, Immunology, Pharmacotherapy +14

Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open‐label extension analysis

Edward Keystone, Roy Fleischmann, Paul Emery et al. · Arthritis & Rheumatism · 2007 · 334 citations

Medicine, Internal Medicine, Pharmacotherapy +15

Mononuclear cells in myopathies: Quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies

Andrew G. Engel, Kiichi Arahata · Human Pathology · 1986 · 309 citations

Life Sciences, Immunology, Pathology +9

Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials

Ronald van Vollenhoven, Paul Emery, Clifton O. Bingham et al. · The Journal of Rheumatology · 2010 · 286 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +17